Agoraphobia without panic disorder
Methodology & AI Transparency ⓘ
Agoraphobia without panic disorder Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as F40.02, Agoraphobia without panic disorder falls under Anxiety & PTSD management, where cognitive-behavioral exposure readiness in Agoraphobia without panic disorder (F40.02: evaluation) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Agoraphobia without panic disorder uses ICD-10 F40.02 across Anxiety & PTSD specialty care.
- 3 Typical cash cost range: Workup highlights for Agoraphobia without panic disorder (F40.02): cognitive-behavioral exposure readiness in Agoraphobia without panic disorder (F40.02: evaluation).
- 4 Top reported side effects / signs: Longitudinal Agoraphobia without panic disorder monitoring tracks Resting Heart Rate in Agoraphobia without panic disorder (F40.02: Variability (HRV)) toward Stable upward personal trend (F40.02).
Ask our AI Specialists anything about Agoraphobia without panic disorder
What Is Agoraphobia without panic disorder?
Designated in federal medical registries as F40.02, Agoraphobia without panic disorder falls under Anxiety & PTSD management, where cognitive-behavioral exposure readiness in Agoraphobia without panic disorder (F40.02: evaluation) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Agoraphobia without panic disorder (F40.02) center on GABAergic-glutamatergic excitation imbalance [Agoraphobia without panic disorder F40.02]. targeted anxiety & ptsd interventions aim to normalize Resting Heart Rate in Agoraphobia without panic disorder (F40.02: Variability (HRV)).
Common Symptoms & Clinical Signs
- • Presentation of Agoraphobia without panic disorder (F40.02): avoidance of triggers, in Agoraphobia without panic disorder (F40.02: intrusive trauma memories,)
- • Secondary Agoraphobia without panic disorder clinical sign: excessive, hard-to-control anticipatory in Agoraphobia without panic disorder (F40.02: worry or intrusive)
- • Symptom flares in Agoraphobia without panic disorder correlating with Resting Heart Rate in Agoraphobia without panic disorder (F40.02: Variability (HRV)) deviation outside Stable upward personal trend (F40.02)
- • Functional anxiety & ptsd impact requiring cognitive-behavioral exposure readiness in Agoraphobia without panic disorder (F40.02: evaluation) evaluation (F40.02)
Agoraphobia without panic disorder Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F40.02 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anxiety, OCD & Trauma Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: Resting Heart Rate in Agoraphobia without panic disorder (F40.02: Variability (HRV)) | Stable upward personal trend (F40.02) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Ferritin in Agoraphobia without panic disorder (F40.02: Rule-Out) | TSH 0.8–2.5 mIU/L; Ferritin > 50 ng/mL (F40.02) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: GAD-7 Anxiety Severity in Agoraphobia without panic disorder (F40.02: Score) | < 4 (minimal anxiety) (F40.02) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Agoraphobia without panic disorder
Treatment selection for Agoraphobia without panic disorder depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Agoraphobia without panic disorder)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| What the Latest Evidence Really Says About Drug treatment for panic disorder with or without agoraphobia: systematic review The findings suggest that SSRIs provide high rates of full symptom relief with low risk of side effects for the treatment of panic disorder. BMJ (Clinical research ed.) • 2022-01-19 • Meta-Analysis | Multi-cohort | 92/100 | PMID 35045991 ↗ |
| Can This Approach Help? Inside the Latest Research on Self-compassion mediates treatment effects in MDMA-assisted therapy for Conclusions: These findings suggest that self-compassion may play a critical role in the therapeutic effects of MDMA-AT. European journal of psychotraumatology • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40331914 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy, safety, and how the body absorbs the medicine of nanodispersible Nanodispersible CBD was therapeutically safe with no serious side effects, well tolerated, and effective for the treatment of mild to moderate anxiety, as well as associated depression and sleep quality disturbances. Asian journal of psychiatry • 2024-07-15 • Phase III Randomized Trial | N = 89 | 88/100 | PMID 38797087 ↗ |
| Can This Approach Help? Inside the Latest Research on Instructed increase in fear activation during exposure exercises does not enhance At the follow-up assessment, both treatment variants were equally effective in all outcomes. Behaviour research and therapy • 2026-02-15 • Phase III Randomized Trial | N = 124 | 82/100 | PMID 41539132 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of a Smartphone-Based Digital Therapeutic (Anzeilax) in Generalized Anzeilax demonstrated clinically meaningful efficacy in reducing anxiety symptoms when combined with TAU. Journal of medical Internet research • 2025-10-14 • Randomized Controlled Trial | N = 48 | 82/100 | PMID 41086425 ↗ |
Agoraphobia without panic disorder Patient Community & “People Like Me” Threads
Filter Agoraphobia without panic disorder community threads and patient logs by age, biological sex, dosage, and treatment duration.